CRINETICS PHARM (CRNX)
(Delayed Data from NSDQ)
$33.91 USD
-1.57 (-4.43%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $34.01 +0.10 (0.29%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CRNX 33.91 -1.57(-4.43%)
Will CRNX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CRNX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRNX
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates
Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q2 Earnings Expected to Decline
CRNX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ionis Pharmaceuticals (IONS) Moves 9.1% Higher: Will This Strength Last?
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates
Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates
Other News for CRNX
20 Day Moving Average Support appears for CRNX after 4.43% move
Interesting CRNX Put And Call Options For November 21st
CRNX forms MACD Bullish Signal Line Cross on September 19
Is CRNX positioned for a breakdown? MACD Bearish Signal Line Cross shows up after gaining 0.29%
The technical outlook for CRNX is unchanged after it rises 0.98% on September 16